Baidu
map

君实生物重组全人源抗SARS-CoV-2单克隆抗体注射液进展良好

2020-10-08 亿欧 亿欧

君实生物公布其重组全人源抗SARS-CoV-2单克隆抗体注射液联合疗法的进展,在降低病毒载量、减轻症状及降低和冠状病毒相关的住院及急诊治疗方面均显示出良好疗效。

君实生物公布其重组全人源抗SARS-CoV-2单克隆抗体注射液联合疗法的进展,在降低病毒载量、减轻症状及降低和冠状病毒相关的住院及急诊治疗方面均显示出良好疗效。

LY-CoV555为礼来与AbCellera公司合作开发的一款有效中和IgG1的单克隆抗体,直接抑制SARS-CoV-2病毒的棘突蛋白。该抗体的设计原理为阻断病毒附着、进入人体细胞,从而中和该病毒、具有潜在的预防和治疗COVID-19的效果。

JS016 (LY-CoV016)是一款重组全人源单克隆中和抗体,以高亲和力特异性结合SARS-CoV-2表面刺突蛋白受体结构域,并能有效阻断病毒与宿主细胞表面受体ACE2的结合。JS016(LY-CoV016)在预防及治疗SARS-CoV-2感染方面均具有良好疗效。

君实生物与中国科学院微生物研究所共同开发JS016后,美国礼来制药公司从君实生物引进JS016, 君实生物将主导大中华地区(包括中国大陆、香港特别行政区、澳门特别行政区及台湾地区)的开发活动,而礼来制药将主导全球其他地区的开发活动。

君实生物已在中国健康受试者中完成了评估安全性、耐受性、药代动力学特征及免疫原性的I期研究,并正在开展国际多中心的Ib/II期临床试验。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937962, encodeId=708e193e96274, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 10 03:36:50 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660231, encodeId=f0de166023176, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Jan 27 16:36:50 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891327, encodeId=32dc89132ea6, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b032823267, createdName=691273246, createdTime=Sun Oct 11 22:18:59 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321228, encodeId=6660132122883, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586594, encodeId=b535158659459, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64990, encryptionId=f87c6499085, topicName=注射液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890729, encodeId=a082890e290b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Oct 09 09:50:34 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2021-09-10 hukaixun
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937962, encodeId=708e193e96274, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 10 03:36:50 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660231, encodeId=f0de166023176, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Jan 27 16:36:50 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891327, encodeId=32dc89132ea6, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b032823267, createdName=691273246, createdTime=Sun Oct 11 22:18:59 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321228, encodeId=6660132122883, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586594, encodeId=b535158659459, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64990, encryptionId=f87c6499085, topicName=注射液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890729, encodeId=a082890e290b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Oct 09 09:50:34 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2021-01-27 aids221
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937962, encodeId=708e193e96274, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 10 03:36:50 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660231, encodeId=f0de166023176, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Jan 27 16:36:50 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891327, encodeId=32dc89132ea6, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b032823267, createdName=691273246, createdTime=Sun Oct 11 22:18:59 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321228, encodeId=6660132122883, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586594, encodeId=b535158659459, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64990, encryptionId=f87c6499085, topicName=注射液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890729, encodeId=a082890e290b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Oct 09 09:50:34 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-11 691273246

    点赞

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1937962, encodeId=708e193e96274, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 10 03:36:50 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660231, encodeId=f0de166023176, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Jan 27 16:36:50 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891327, encodeId=32dc89132ea6, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b032823267, createdName=691273246, createdTime=Sun Oct 11 22:18:59 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321228, encodeId=6660132122883, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586594, encodeId=b535158659459, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64990, encryptionId=f87c6499085, topicName=注射液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890729, encodeId=a082890e290b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Oct 09 09:50:34 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-10 小刀医生
  5. [GetPortalCommentsPageByObjectIdResponse(id=1937962, encodeId=708e193e96274, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 10 03:36:50 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660231, encodeId=f0de166023176, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Jan 27 16:36:50 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891327, encodeId=32dc89132ea6, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b032823267, createdName=691273246, createdTime=Sun Oct 11 22:18:59 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321228, encodeId=6660132122883, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586594, encodeId=b535158659459, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64990, encryptionId=f87c6499085, topicName=注射液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890729, encodeId=a082890e290b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Oct 09 09:50:34 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1937962, encodeId=708e193e96274, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 10 03:36:50 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660231, encodeId=f0de166023176, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Jan 27 16:36:50 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891327, encodeId=32dc89132ea6, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b032823267, createdName=691273246, createdTime=Sun Oct 11 22:18:59 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321228, encodeId=6660132122883, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586594, encodeId=b535158659459, content=<a href='/topic/show?id=f87c6499085' target=_blank style='color:#2F92EE;'>#注射液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64990, encryptionId=f87c6499085, topicName=注射液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 10 13:36:50 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890729, encodeId=a082890e290b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Oct 09 09:50:34 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-09 ms3000000546723755

    厉害

    0

相关资讯

抗COVID-19单克隆抗体候选药物CT-P59:I期临床试验获得积极结果

制药公司Celltrion近日公布了CT-P59(抗COVID-19单克隆抗体候选药物)的I期临床试验的中期结果,结果显示,CT-P59具有良好的安全性、耐受性和药代动力学。

新型单克隆抗体治疗黄热病:安全有效

一项在《新英格兰医学杂志》(NEJM)的研究展示单克隆抗体TY014治疗黄热病(YF)的安全性和有效性。

Sci Rep:在小鼠同种异体角膜移植中抗LAP单克隆抗体下调CD4+ LAP+ T细胞

北京同仁眼科中心和首都医科大学附属北京佑安医院眼科的Li S近日在Sci Rep发表了一项工作,他们通过使用抗LAP mAb,下调其表达,来研究CD4+ LAP+ T细胞在小鼠角膜移植物存活中的作用。

张会来教授:PD-1/PD-L1单克隆抗体在恶性淋巴瘤的研究方向与热点问题

免疫检查点已成为当今肿瘤治疗最热门的领域之一,PD-1/ PD-L1作为免疫检查点最重要代表,目前已有6个抗体成功获得美国FDA 批准,包括三个PD-1抗体Nivolumab、Pembrolizumab、Cemiplimab,三个PD-L1抗体Atezolizumab、Avelumab、Durvalumab。我国NMPA也批准5个抗体,包括Nivolumab、Pembrolizumab、特瑞普利单

Nat Commun:抗GARP:TGF-β1单抗能克服PD-1/PD-L1抑制剂耐药性

调节性T细胞(Treg)的免疫抑制作用对于外周免疫耐受的维持是不可或缺的,在癌症或慢性感染中该作用具有有害性。因此,在癌症患者中靶向Treg细胞及其功能的治疗策略的研究显得尤为重要。

Science:CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘

2020年8月14日,《Science》上发表了一篇论文,揭示了CD20治疗性抗体的差异结合机制。

Baidu
map
Baidu
map
Baidu
map